EndoStim is a venture-backed medical device company based in St. Louis, Missouri, and the Hague, the Netherlands.
EndoStim's neurostimulation therapy is a minimally-invasive, long-term treatment for severe reflux patients that directly targets the patient's weak or dysfunctional lower esophageal sphincter (LES) muscle between the stomach and the esophagus – often the underlying cause of reflux.
The EndoStim system is CE Marked for patients with gastro-esophageal reflux disease with symptom duration of 6 months or longer. EndoStim is available in a number of countries throughout Europe, Latin America, and Asia Pacific. The EndoStim system is not approved for sale in the US and is limited by US federal law to investigational use only.
Deutsche Website für Patienten:
www.reflux-behandlung.de
Schweizer Website für Patienten:
www.refluxtherapie.ch
Sitio web del Paciente de Colombia:
www.endostim.com.co
Sitio web del Paciente de México:
www.endostim.com.mx
UK Patient Website:
www.learnaboutreflux.com
EndoStim's neurostimulation therapy is a minimally-invasive, long-term treatment for severe reflux patients that directly targets the patient's weak or dysfunctional lower esophageal sphincter (LES) muscle between the stomach and the esophagus – often the underlying cause of reflux.
The EndoStim system is CE Marked for patients with gastro-esophageal reflux disease with symptom duration of 6 months or longer. EndoStim is available in a number of countries throughout Europe, Latin America, and Asia Pacific. The EndoStim system is not approved for sale in the US and is limited by US federal law to investigational use only.
Deutsche Website für Patienten:
www.reflux-behandlung.de
Schweizer Website für Patienten:
www.refluxtherapie.ch
Sitio web del Paciente de Colombia:
www.endostim.com.co
Sitio web del Paciente de México:
www.endostim.com.mx
UK Patient Website:
www.learnaboutreflux.com
Location: United States
Total raised: $31M
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.05.2016 | Series D | $25M | - |
| 19.07.2010 | Series B | $6M | - |
Mentions in press and media 8
| Date | Title | Description |
| 03.11.2016 | First patient implanted in EndoStim's LESS trial for GERD | EndoStim, Inc., announced that the first patient has been implanted with the EndoStim device in the LESS GERD trial, at the University of Southern California. |
| 13.05.2016 | EndoStim Secures $25M in Series D | ST. LOUIS, MA, Medical device company has completed a Series D financing round of $25 million. >> Click here for more funding data on EndoStim >> To export EndoStim funding data to PDF and Excel, click here EndoStim, Inc.... |
| 12.05.2016 | EndoStim Completes $25M Series D Funding | EndoStim, Inc., a St. Louis, Missouri, and Nijmegen, The Netherlands-based medical device company that has developed neurostimulation therapy for gastroesophageal reflux disease (GERD), completed a $25m Series D financing round. Endeavour V... |
| 01.10.2014 | EndoStim targets $36m IPO | EndoStim said it hopes to raise nearly $36 million in an initial public offering, with plans to plow $10 million into clinical studies of its system to treat severe gastroesophageal reflux disease and another $14 million to commercialize th... |
| 25.03.2013 | EndoStim takes funding round to $11M | Wall Street Beat | EndoStim added another tranche to its $16.5 million equity round, according to a regulatory filing, saying it’s added some $11.2 million to its coffers as it develops a pacemaker-like implant to treat gastro-esophageal reflux disease. The r... |
| 03.01.2013 | Implantable device addresses the cause of severe GERD with electrical stimulation | While antacids, H2 blockers and proton pump inhibitors can be used to treat occasional heartburn, there is concern about side effects from long-term use of H2 blockers and PPIs, which suppress the production of stomach acid. EndoStim’s devi... |
| 19.07.2010 | EndoStim Raises $6M in Series B Equity Financing | EndoStim, Inc., a St. Louis-based medical device company developing minimally-invasive interventional therapies to treat gastrointestinal and urological neuro-muscular disorders, has raised $6m in Series B equity financing. The round was le... |
| - | Implantable device addresses the cause of severe GERD with electrical stimulation | Researchers and medical device companies are using electrical stimulation in new products to address pain, sleep apnea, paralysis and ALS. But a young St. Louis company is applying electrical stimulation to gastroesophageal reflux disease t... |